Musculoskeletal/Rheumatology

Latest News

FDA Approves Second Biosimilar of Actemra
FDA Approves Second Biosimilar of Actemra

March 7th 2024

The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.

Celltrion USA Seeks Approval for Actemra Biosimilar
Celltrion USA Seeks Approval for Actemra Biosimilar

January 29th 2024

FDA Approves First Biosimilar of Arthritis Med Actemra
FDA Approves First Biosimilar of Arthritis Med Actemra

October 2nd 2023

Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDA

March 22nd 2023

FDA Approves Kevzara for Inflammatory Rheumatic Disease
FDA Approves Kevzara for Inflammatory Rheumatic Disease

March 1st 2023

More News

© 2024 MJH Life Sciences

All rights reserved.